Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 4
2(40.0%)
5Total
N/A(3)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06878573Completed

Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

Role: lead

NCT03921372Not ApplicableCompleted

Isometric Exercise in NTG

Role: lead

NCT03804099Phase 4Completed

Effect Aflibercept on Ocular Perfusion

Role: lead

NCT03391518Not ApplicableUnknown

Evaluation of Blood Flow Regulation With Laser Speckle Flowgraphy

Role: lead

NCT03318510Not ApplicableUnknown

LSFG in Patients With Normal Tension Glaucoma Tension Glaucoma

Role: lead

NCT02812004Phase 4Unknown

New Horizons in the Treatment of Vitreous Floaters

Role: lead

NCT02614625Unknown

Spectral-domain Optical Coherence Tomography of the Eye

Role: lead

All 7 trials loaded